A Study of LY3819469 in Healthy Participants

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469

This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) [Lp(a)] levels. How the body processes the study drug and the effect of the study drug on blood Lp(a) levels will also be investigated. Part B will mainly evaluate the safety and tolerability of LY3819469 as well as how the body processes the study drug in Japanese participants. The study may last up to 53 and 29 weeks for each participant in Parts A and B, respectively.

Inclusion Criteria:

• Female participants must not be able to get pregnant and male participants must agree to adhere to contraception restrictions
• Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
• For Part B, participants should be of first-generation Japanese origin

Exclusion Criteria:

• Are currently participating in or completed a clinical trial within the last 30 days
• Are heavy alcohol drinkers or heavy cigarette smokers
• Have donated blood of more than 500 milliliters (mL) in the last 3 months